



SPAFID CONNECT

Informazione Regolamentata n. 0472-17-2019	Data/Ora Ricezione 21 Marzo 2019 17:51:32	MTA - Star
--	---	------------

Societa' : BB BIOTECH

Identificativo : 115534

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : REGEM

Data/Ora Ricezione : 21 Marzo 2019 17:51:32

Data/Ora Inizio : 21 Marzo 2019 17:51:33

Diffusione presunta

Oggetto : BB Biotech AG: Shareholders at the
general meeting vote in favor of all
proposals and approve the dividend of CHF
3.05

Testo del comunicato

Vedi allegato.

Media Release as of March 21, 2019

BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.05

All proposals of BB Biotech AG's Board of Directors were approved by shareholders at its Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.05 per share. Payment will be made on March 27, 2019, the date of record is March 26, 2019 and the ex-dividend date is March 25, 2019.

Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another one-year term of office. Dr. Thomas von Planta was newly elected to the Board of Directors.

Thomas von Planta brings profound expertise from the financial sector to the Board of Directors. He has been the business owner and manager of CorFinAd AG since 2006, a Zurich-based consultancy for M&A and capital market transactions. Prior to that he worked for Vontobel Group as Head Investment Banking a.i. and Head Corporate Finance and served on its Extended Executive Board. He was Chairman of the Board of Directors of Bellevue Group AG and was not standing for re-election at the Annual General Meeting on March 19, 2019. Thomas von Planta also sits on the Board of Directors of Bâloise Holding AG, Basel.

For further information:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28

Thomas Egger, teq@te-communications.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-17

Numero di Pagine: 3